Global Peripheral Arterial Disease (PAD) Therapeutics Market Size, Status and Forecast 2019-2025

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Peripheral Arterial Disease (PAD) Therapeutics Revenue
• 1.4 Market by Type
  • 1.4.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Anti-Platelet Drugs
  • 1.4.3 Dual Antiplatelet Therapy Drugs
  • 1.4.4 Others
• 1.5 Market by Application
  • 1.5.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Application: 2020 VS 2026
  • 1.5.2 Hospitals
  • 1.5.3 Clinics
  • 1.5.4 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Perspective (2015-2026)
• 2.2 Global Peripheral Arterial Disease (PAD) Therapeutics Growth Trends by Regions
  • 2.2.1 Peripheral Arterial Disease (PAD) Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Peripheral Arterial Disease (PAD) Therapeutics Historic Market Share by Regions (2015-2020)
  • 2.2.3 Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Peripheral Arterial Disease (PAD) Therapeutics Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Peripheral Arterial Disease (PAD) Therapeutics Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Peripheral Arterial Disease (PAD) Therapeutics Players by Market Size
  • 3.1.1 Global Top Peripheral Arterial Disease (PAD) Therapeutics Players by Revenue (2015-2020)
  • 3.1.2 Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Peripheral Arterial Disease (PAD) Therapeutics Market Concentration Ratio
  • 3.2.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Peripheral Arterial Disease (PAD) Therapeutics Revenue in 2019
• 3.3 Peripheral Arterial Disease (PAD) Therapeutics Key Players Head office and Area Served
• 3.4 Key Players Peripheral Arterial Disease (PAD) Therapeutics Product Solution and Service
• 3.5 Date of Enter into Peripheral Arterial Disease (PAD) Therapeutics Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global Peripheral Arterial Disease (PAD) Therapeutics Historic Market Size by Type (2015-2020)
• 4.2 Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

• 5.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020)
• 5.2 Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size (2015-2020)
• 6.2 Peripheral Arterial Disease (PAD) Therapeutics Key Players in North America (2019-2020)
• 6.3 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2015-2020)
• 6.4 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size (2015-2020)
• 7.2 Peripheral Arterial Disease (PAD) Therapeutics Key Players in Europe (2019-2020)
• 7.3 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2015-2020)
• 7.4 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020)

8 China

• 8.1 China Peripheral Arterial Disease (PAD) Therapeutics Market Size (2015-2020)
• 8.2 Peripheral Arterial Disease (PAD) Therapeutics Key Players in China (2019-2020)
• 8.3 China Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2015-2020)
• 8.4 China Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Peripheral Arterial Disease (PAD) Therapeutics Market Size (2015-2020)
• 9.2 Peripheral Arterial Disease (PAD) Therapeutics Key Players in Japan (2019-2020)
• 9.3 Japan Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2015-2020)
• 9.4 Japan Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Peripheral Arterial Disease (PAD) Therapeutics Market Size (2015-2020)
• 10.2 Peripheral Arterial Disease (PAD) Therapeutics Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2015-2020)
• 10.4 Southeast Asia Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020)

11 India

• 11.1 India Peripheral Arterial Disease (PAD) Therapeutics Market Size (2015-2020)
• 11.2 Peripheral Arterial Disease (PAD) Therapeutics Key Players in India (2019-2020)
• 11.3 India Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2015-2020)
• 11.4 India Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Peripheral Arterial Disease (PAD) Therapeutics Market Size (2015-2020)
• 12.2 Peripheral Arterial Disease (PAD) Therapeutics Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2015-2020)
• 12.4 Central & South America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 AstraZeneca Plc. (UK)
  • 13.1.1 AstraZeneca Plc. (UK) Company Details
  • 13.1.2 AstraZeneca Plc. (UK) Business Overview
  • 13.1.3 AstraZeneca Plc. (UK) Peripheral Arterial Disease (PAD) Therapeutics Introduction
  • 13.1.4 AstraZeneca Plc. (UK) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020))
  • 13.1.5 AstraZeneca Plc. (UK) Recent Development
• 13.2 Bayer HealthCare Pharmaceuticals (Germany)
  • 13.2.1 Bayer HealthCare Pharmaceuticals (Germany) Company Details
  • 13.2.2 Bayer HealthCare Pharmaceuticals (Germany) Business Overview
  • 13.2.3 Bayer HealthCare Pharmaceuticals (Germany) Peripheral Arterial Disease (PAD) Therapeutics Introduction
  • 13.2.4 Bayer HealthCare Pharmaceuticals (Germany) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
  • 13.2.5 Bayer HealthCare Pharmaceuticals (Germany) Recent Development
• 13.3 Bristol-Myers Squibb Company (US)
  • 13.3.1 Bristol-Myers Squibb Company (US) Company Details
  • 13.3.2 Bristol-Myers Squibb Company (US) Business Overview
  • 13.3.3 Bristol-Myers Squibb Company (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
  • 13.3.4 Bristol-Myers Squibb Company (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
  • 13.3.5 Bristol-Myers Squibb Company (US) Recent Development
• 13.4 Merck & Co., Inc. (US)
  • 13.4.1 Merck & Co., Inc. (US) Company Details
  • 13.4.2 Merck & Co., Inc. (US) Business Overview
  • 13.4.3 Merck & Co., Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
  • 13.4.4 Merck & Co., Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
  • 13.4.5 Merck & Co., Inc. (US) Recent Development
• 13.5 Proteon Therapeutics, Inc. (US)
  • 13.5.1 Proteon Therapeutics, Inc. (US) Company Details
  • 13.5.2 Proteon Therapeutics, Inc. (US) Business Overview
  • 13.5.3 Proteon Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
  • 13.5.4 Proteon Therapeutics, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
  • 13.5.5 Proteon Therapeutics, Inc. (US) Recent Development
• 13.6 Sanofi S.A. (France)
  • 13.6.1 Sanofi S.A. (France) Company Details
  • 13.6.2 Sanofi S.A. (France) Business Overview
  • 13.6.3 Sanofi S.A. (France) Peripheral Arterial Disease (PAD) Therapeutics Introduction
  • 13.6.4 Sanofi S.A. (France) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
  • 13.6.5 Sanofi S.A. (France) Recent Development
• 13.7 Symic Bio, Inc. (US)
  • 13.7.1 Symic Bio, Inc. (US) Company Details
  • 13.7.2 Symic Bio, Inc. (US) Business Overview
  • 13.7.3 Symic Bio, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
  • 13.7.4 Symic Bio, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
  • 13.7.5 Symic Bio, Inc. (US) Recent Development
• 13.8 TheraVasc Inc. (US)
  • 13.8.1 TheraVasc Inc. (US) Company Details
  • 13.8.2 TheraVasc Inc. (US) Business Overview
  • 13.8.3 TheraVasc Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
  • 13.8.4 TheraVasc Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
  • 13.8.5 TheraVasc Inc. (US) Recent Development
• 13.9 AnGes MG, Inc. (Japan)
  • 13.9.1 AnGes MG, Inc. (Japan) Company Details
  • 13.9.2 AnGes MG, Inc. (Japan) Business Overview
  • 13.9.3 AnGes MG, Inc. (Japan) Peripheral Arterial Disease (PAD) Therapeutics Introduction
  • 13.9.4 AnGes MG, Inc. (Japan) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
  • 13.9.5 AnGes MG, Inc. (Japan) Recent Development
• 13.10 Athersys, Inc. (US)
  • 13.10.1 Athersys, Inc. (US) Company Details
  • 13.10.2 Athersys, Inc. (US) Business Overview
  • 13.10.3 Athersys, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
  • 13.10.4 Athersys, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
  • 13.10.5 Athersys, Inc. (US) Recent Development
• 13.11 Betagenon AB (Sweden)
  • 10.11.1 Betagenon AB (Sweden) Company Details
  • 10.11.2 Betagenon AB (Sweden) Business Overview
  • 10.11.3 Betagenon AB (Sweden) Peripheral Arterial Disease (PAD) Therapeutics Introduction
  • 10.11.4 Betagenon AB (Sweden) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
  • 10.11.5 Betagenon AB (Sweden) Recent Development
• 13.12 miRagen Therapeutics, Inc. (US)
  • 10.12.1 miRagen Therapeutics, Inc. (US) Company Details
  • 10.12.2 miRagen Therapeutics, Inc. (US) Business Overview
  • 10.12.3 miRagen Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
  • 10.12.4 miRagen Therapeutics, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
  • 10.12.5 miRagen Therapeutics, Inc. (US) Recent Development
• 13.13 Multi Gene Vascular Systems Ltd (Israel)
  • 10.13.1 Multi Gene Vascular Systems Ltd (Israel) Company Details
  • 10.13.2 Multi Gene Vascular Systems Ltd (Israel) Business Overview
  • 10.13.3 Multi Gene Vascular Systems Ltd (Israel) Peripheral Arterial Disease (PAD) Therapeutics Introduction
  • 10.13.4 Multi Gene Vascular Systems Ltd (Israel) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
  • 10.13.5 Multi Gene Vascular Systems Ltd (Israel) Recent Development
• 13.14 ViroMed Co. Ltd. (Korea)
  • 10.14.1 ViroMed Co. Ltd. (Korea) Company Details
  • 10.14.2 ViroMed Co. Ltd. (Korea) Business Overview
  • 10.14.3 ViroMed Co. Ltd. (Korea) Peripheral Arterial Disease (PAD) Therapeutics Introduction
  • 10.14.4 ViroMed Co. Ltd. (Korea) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
  • 10.14.5 ViroMed Co. Ltd. (Korea) Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer